Chatwin 2016.

Methods	Study design: multi‐centre, single‐blinded, stratified randomised controlled trial in United Kingdom Duration: 52 weeks Setting: primary and secondary clinics
Participants	Population: 68 adults recruited from outpatient and inpatient clinics at Royal Brompton & Harefield NHS Foundation Trust, West Middlesex University Hospital, and St George’s University Hospital Baseline characteristics: % Male: 63 all, Mean age: 65.3 all, % White: not reported, % African: not reported, % LTOT: 59 all, % Home oxygen: not reported, % Anxiety and depression 8 (4) all and 7 (4) all, Baseline medications: not reported, FEV₁: all 0.9 (0.5), FVC: all 2.1 (0.9), FEV₁/FVC: not reported, Current smokers (n): not reported, GOLD stage: all 3 (1), COPD exacerbations last 12 months: not reported, Hospitalisations in past 12 months: not reported Inclusion criteria: ≥ 18 years old, COPD or chronic respiratory failure due to another chronic respiratory disease, admitted exacerbation in previous 6 months, met criteria for LTOT or had oxygen saturation level ≤ 90% on air for past admission Exclusion criteria: cognitive impairment that impairs understanding of the trial or use of telemonitoring, age < 18 years
Interventions	Measurements taken at baseline and at 3, 6, and 12 months Treatment arms Telemonitoring monitor by broadband link to care team Daily measurements and data sent Monday through Friday Personalised care plan
Outcomes	Primary outcomes: time to first hospital admission for exacerbation Secondary outcomes: hospital admissions, general practitioner (GP) consultations and home visits by nurses, quality of life measured by EuroQoL‐5D and hospital anxiety and depression (HAD) scale, self‐efficacy score
Notes	Funding: National Institute for Health Research (NIHR) under the Collaborations for Leadership in Applied Health Research and Care (CLAHRC) programme for North West London Other identifier:NCT02180919